Bilgehan Yüzbaşıoğlu1, Müge Ustaoğlu2, Şule Yüzbaşıoğlu3, Ulaş Emre Akbulut4, Kamil Özdil5. 1. Department of Gastroenterology, Bursa State Hospital, Bursa, Turkey. 2. Department of Gastroenterology, Ondokuz Mayıs University School of Medicine, Samsun, Turkey. 3. Department of Hematology, Bursa Higher Specialization Training and Research Hospital, Bursa, Turkey. 4. Department of Pediatric Gastroenterology, Hepatology and Nutrition, Health Sciences University, Antalya Trainig and Research Hospital, Antalya, Turkey. 5. Department of Gastroenterology, Health Sciences University, Ümraniye Training and Research Hospital, İstanbul, Turkey.
Abstract
BACKGROUND/AIMS: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13) in patients with IBD and to assess their possible role in the etiopathogenesis of the disease. MATERIALS AND METHODS: Thirty-four patients with IBD (23 ulcerative colitis and 11 Crohn's disease) and 20 healthy controls were included in the present study. TAFI, TFPI, and ADAMTS-13 concentrations were determined by enzyme-linked immunosorbent assay. RESULTS: Mean TAFI, TFPI, and ADAMTS-13 concentrations in the patient group were 17.75 ng/ml, 72.10 ng/ml, and 14.90 U/l, respectively. In the control group, these values were 117.10 ng/ml, 300 ng/ml, and 191.55 U/l, respectively. TAFI, TFPI, and ADAMTS-13 values were significantly lower in the patient group than in the control group (all p<0.01). CONCLUSION: TAFI, TFPI, and ADAMTS-13 levels were significantly lower in the patient group. These findings indicate the presence of a clear, multifactorial imbalance in the coagulation-fibrinolytic system in the patient group. It is also possible that this imbalance in the coagulation and fibrinolytic system may play a role in the still unclear etiopathogenesis of the disease.
BACKGROUND/AIMS: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13) in patients with IBD and to assess their possible role in the etiopathogenesis of the disease. MATERIALS AND METHODS: Thirty-four patients with IBD (23 ulcerative colitis and 11 Crohn's disease) and 20 healthy controls were included in the present study. TAFI, TFPI, and ADAMTS-13 concentrations were determined by enzyme-linked immunosorbent assay. RESULTS: Mean TAFI, TFPI, and ADAMTS-13 concentrations in the patient group were 17.75 ng/ml, 72.10 ng/ml, and 14.90 U/l, respectively. In the control group, these values were 117.10 ng/ml, 300 ng/ml, and 191.55 U/l, respectively. TAFI, TFPI, and ADAMTS-13 values were significantly lower in the patient group than in the control group (all p<0.01). CONCLUSION:TAFI, TFPI, and ADAMTS-13 levels were significantly lower in the patient group. These findings indicate the presence of a clear, multifactorial imbalance in the coagulation-fibrinolytic system in the patient group. It is also possible that this imbalance in the coagulation and fibrinolytic system may play a role in the still unclear etiopathogenesis of the disease.
Authors: Cristina Suárez Ferrer; María Isabel Vera Mendoza; Leticia Amo San Román; Yago González Lama; Marta Calvo Moya; Mercedes García Casas; Luis Abreu García Journal: Gastroenterol Hepatol Date: 2012-10-02 Impact factor: 2.102
Authors: R Ennaifer; A Moussa; L Mouelhi; M Salem; S Bouzaidi; R Debbeche; S Trabelsi; T Najjar Journal: Acta Gastroenterol Belg Date: 2009 Jul-Sep Impact factor: 1.316
Authors: Hendrik B Feys; Maria T Canciani; Flora Peyvandi; Hans Deckmyn; Karen Vanhoorelbeke; Pier M Mannucci Journal: Br J Haematol Date: 2007-06-29 Impact factor: 6.998